AU2015289758B2 - Methods for evaluating lung cancer status - Google Patents

Methods for evaluating lung cancer status Download PDF

Info

Publication number
AU2015289758B2
AU2015289758B2 AU2015289758A AU2015289758A AU2015289758B2 AU 2015289758 B2 AU2015289758 B2 AU 2015289758B2 AU 2015289758 A AU2015289758 A AU 2015289758A AU 2015289758 A AU2015289758 A AU 2015289758A AU 2015289758 B2 AU2015289758 B2 AU 2015289758B2
Authority
AU
Australia
Prior art keywords
lung cancer
genes
subject
patients
bronchoscopy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015289758A
Other languages
English (en)
Other versions
AU2015289758A1 (en
Inventor
Michael Elashoff
Duncan H. Whitney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Veracyte Inc
Original Assignee
Veracyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veracyte Inc filed Critical Veracyte Inc
Publication of AU2015289758A1 publication Critical patent/AU2015289758A1/en
Assigned to VERACYTE, INC. reassignment VERACYTE, INC. Request for Assignment Assignors: ALLEGRO DIAGNOSTICS CORP.
Priority to AU2021218178A priority Critical patent/AU2021218178A1/en
Application granted granted Critical
Publication of AU2015289758B2 publication Critical patent/AU2015289758B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/30—Microarray design
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Software Systems (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Evolutionary Computation (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
AU2015289758A 2014-07-14 2015-07-14 Methods for evaluating lung cancer status Active AU2015289758B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021218178A AU2021218178A1 (en) 2014-07-14 2021-08-20 Methods for evaluating lung cancer status

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462024456P 2014-07-14 2014-07-14
US62/024,456 2014-07-14
US201562160403P 2015-05-12 2015-05-12
US62/160,403 2015-05-12
PCT/US2015/040437 WO2016011068A1 (en) 2014-07-14 2015-07-14 Methods for evaluating lung cancer status

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021218178A Division AU2021218178A1 (en) 2014-07-14 2021-08-20 Methods for evaluating lung cancer status

Publications (2)

Publication Number Publication Date
AU2015289758A1 AU2015289758A1 (en) 2017-02-02
AU2015289758B2 true AU2015289758B2 (en) 2021-09-09

Family

ID=55078998

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015289758A Active AU2015289758B2 (en) 2014-07-14 2015-07-14 Methods for evaluating lung cancer status
AU2021218178A Abandoned AU2021218178A1 (en) 2014-07-14 2021-08-20 Methods for evaluating lung cancer status

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021218178A Abandoned AU2021218178A1 (en) 2014-07-14 2021-08-20 Methods for evaluating lung cancer status

Country Status (8)

Country Link
US (2) US20160130656A1 (https=)
EP (2) EP3169814B1 (https=)
JP (2) JP6775499B2 (https=)
KR (1) KR102461014B1 (https=)
CN (2) CN106795565B (https=)
AU (2) AU2015289758B2 (https=)
CA (1) CA2954169A1 (https=)
WO (1) WO2016011068A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100035244A1 (en) 2005-04-14 2010-02-11 The Trustees Of Boston University Diagnostic for lung disorders using class prediction
WO2007103541A2 (en) 2006-03-09 2007-09-13 The Trustees Of Boston University Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
JP2010538680A (ja) 2007-09-19 2010-12-16 ザ トラスティーズ オブ ボストン ユニバーシティー 肺疾患に対する薬剤開発のための新規経路の同定
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US8669057B2 (en) 2009-05-07 2014-03-11 Veracyte, Inc. Methods and compositions for diagnosis of thyroid conditions
EP3626308A1 (en) 2013-03-14 2020-03-25 Veracyte, Inc. Methods for evaluating copd status
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
EP3215170A4 (en) 2014-11-05 2018-04-25 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
EP4180531A3 (en) 2016-05-12 2023-08-23 Trustees of Boston University Nasal epithelium gene expression signature and classifier for the prediction of lung cancer
AU2017281099A1 (en) 2016-06-21 2019-01-03 The Wistar Institute Of Anatomy And Biology Compositions and methods for diagnosing lung cancers using gene expression profiles
US10927417B2 (en) 2016-07-08 2021-02-23 Trustees Of Boston University Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions
EP3513344A1 (en) * 2016-09-14 2019-07-24 Philip Morris Products S.a.s. Systems, methods, and gene signatures for predicting a biological status of an individual
US11244764B2 (en) * 2016-12-21 2022-02-08 Cerner Innovation, Inc. Monitoring predictive models
CN110662844A (zh) * 2017-05-22 2020-01-07 内盖夫生物技术国家研究所有限公司 用于肺癌的诊断的生物标志物
JP2020522690A (ja) * 2017-06-02 2020-07-30 ベラサイト インコーポレイテッド 肺疾病の特定又はモニタリング方法及びシステム
US12227808B2 (en) 2017-12-19 2025-02-18 The Wistar Institute Of Anatomy And Biology Compostions and methods for diagnosing lung cancers using gene expression profiles
US12023149B2 (en) 2018-07-02 2024-07-02 3M Innovative Properties Company Sensing system and method for monitoring time-dependent processes
KR102274564B1 (ko) * 2018-07-03 2021-07-07 (주) 프로큐라티오 빅데이터분석기반 암진단장치
CN108998531B (zh) * 2018-08-31 2021-10-01 昆明医科大学第一附属医院 肺癌下调长链非编码rna标志物及其应用
CN109615075B (zh) * 2018-12-14 2022-08-19 大连海事大学 一种基于多层聚类模型的居民日常行为识别方法
US20210287795A1 (en) * 2020-03-12 2021-09-16 Optellum Limited Cad device and method for assisting an estimation of lung disease from medical images
CN111455057B (zh) * 2020-03-30 2021-10-26 中国医学科学院肿瘤医院 用于肺癌诊断的试剂盒、装置及方法
CN114317746B (zh) * 2020-03-30 2022-09-23 中国医学科学院肿瘤医院 外泌体arpc5、ypel2等在肺癌诊断中的应用
CN111863130A (zh) * 2020-04-07 2020-10-30 至本医疗科技（上海）有限公司 肿瘤免疫治疗预后标志物的筛选方法及应用
CN112034185A (zh) * 2020-09-11 2020-12-04 上海市胸科医院 Gpr110、vegfr、cd34在鉴别肺腺癌亚型中的用途
EP4314323A4 (en) * 2021-03-29 2025-06-04 Veracyte, Inc. METHODS AND SYSTEMS FOR IDENTIFYING A LUNG DISORDER
US12094107B2 (en) * 2021-04-07 2024-09-17 Optellum Limited CAD device and method for analyzing medical images
CN113444796B (zh) * 2021-06-29 2023-02-07 浙江医院 与肺癌相关的生物标志物及其在诊断癌症中的应用
KR102417602B1 (ko) * 2021-11-30 2022-07-07 (주)플라스바이오 인공 지능 모델 기반 종양 관리 장치 및 방법
CN114854755B (zh) * 2022-05-30 2023-05-23 陕西师范大学 一种抑制vstm2l表达的慢病毒载体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000098A2 (en) * 2003-06-10 2005-01-06 The Trustees Of Boston University Detection methods for disorders of the lung
WO2009006323A2 (en) * 2007-06-29 2009-01-08 Abbott Laboratories Methods and marker combinations for screening for predisposition to lung cancer
WO2013163568A2 (en) * 2012-04-26 2013-10-31 Allegro Diagnostics Corp. Methods for evaluating lung cancer status

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003234623A1 (en) * 2002-05-16 2003-12-02 Euro-Celtique, S.A. Use of gastrin releasing peptide (grp) and its receptor in cancer screening
CA2552686A1 (en) 2003-11-12 2005-05-26 Trustees Of Boston University Isolation of nucleic acid from mouth epithelial cells
US20100035244A1 (en) * 2005-04-14 2010-02-11 The Trustees Of Boston University Diagnostic for lung disorders using class prediction
WO2007103541A2 (en) 2006-03-09 2007-09-13 The Trustees Of Boston University Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
WO2007142936A2 (en) * 2006-05-30 2007-12-13 Duke University Prediction of lung cancer tumor recurrence
KR101443214B1 (ko) * 2007-01-09 2014-09-24 삼성전자주식회사 폐암 환자 또는 폐암 치료를 받은 폐암 환자의 폐암 재발 위험을 진단하기 위한 조성물, 키트 및 마이크로어레이
AU2008251877A1 (en) 2007-05-08 2008-11-20 Picobella Llc Methods for diagnosing and treating prostate and lung cancer
JP2010538680A (ja) 2007-09-19 2010-12-16 ザ トラスティーズ オブ ボストン ユニバーシティー 肺疾患に対する薬剤開発のための新規経路の同定
US20100055689A1 (en) 2008-03-28 2010-03-04 Avrum Spira Multifactorial methods for detecting lung disorders
GB0811413D0 (en) * 2008-06-20 2008-07-30 Kanton Basel Stadt Gene expression signatures for lung cancers
WO2012006632A2 (en) * 2010-07-09 2012-01-12 Somalogic, Inc. Lung cancer biomarkers and uses thereof
KR20130017525A (ko) * 2011-08-11 2013-02-20 주식회사 젠닥스 대장암, 유방암, 신장암 또는 갑상선암의 조기 진단을 위한 바이오 마커 및 이의 용도
EP2751290A4 (en) * 2011-08-29 2015-07-15 Cardiodx Inc METHOD AND COMPOSITIONS FOR DETERMINING A SMOKE STATUS
CA2799163C (en) * 2011-12-18 2025-01-07 20/20 Genesystems, Inc. Methods and algorithms for aiding in the detection of cancer
US20140220006A1 (en) * 2013-02-01 2014-08-07 Meso Scale Technologies, Llc Lung cancer biomarkers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000098A2 (en) * 2003-06-10 2005-01-06 The Trustees Of Boston University Detection methods for disorders of the lung
WO2009006323A2 (en) * 2007-06-29 2009-01-08 Abbott Laboratories Methods and marker combinations for screening for predisposition to lung cancer
WO2013163568A2 (en) * 2012-04-26 2013-10-31 Allegro Diagnostics Corp. Methods for evaluating lung cancer status

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
S. P. SHRIVER ET AL, , JOURNAL OF THE NATIONAL CANCER INSTITUTE, GB, (2000-01-05), vol. 92, no. 1, doi:10.1093/jnci/92.1.24, ISSN 0027-8874, pages 24 - 33 *

Also Published As

Publication number Publication date
AU2021218178A1 (en) 2021-09-09
JP2017527304A (ja) 2017-09-21
US20160130656A1 (en) 2016-05-12
CN106795565A (zh) 2017-05-31
JP2020182489A (ja) 2020-11-12
JP6775499B2 (ja) 2020-10-28
WO2016011068A1 (en) 2016-01-21
AU2015289758A1 (en) 2017-02-02
CA2954169A1 (en) 2016-01-21
EP3916110A1 (en) 2021-12-01
KR102461014B1 (ko) 2022-10-31
KR20170053617A (ko) 2017-05-16
CN114807368A (zh) 2022-07-29
US20210040562A1 (en) 2021-02-11
EP3169814A1 (en) 2017-05-24
EP3169814B1 (en) 2022-05-04
EP3169814A4 (en) 2018-03-07
CN106795565B (zh) 2022-05-10

Similar Documents

Publication Publication Date Title
AU2015289758B2 (en) Methods for evaluating lung cancer status
Jamshidi et al. Evaluation of cell-free DNA approaches for multi-cancer early detection
JP7813140B2 (ja) 病原体検出のための配列決定データを使用するためのシステムおよび方法
US12297505B2 (en) Algorithms for disease diagnostics
Whitney et al. Derivation of a bronchial genomic classifier for lung cancer in a prospective study of patients undergoing diagnostic bronchoscopy
EP3103046B1 (en) Biomarker signature method, and apparatus and kits therefor
JP5405110B2 (ja) 原発不明がんの原発巣を同定するための方法および材料
US20150088430A1 (en) Methods for evaluating lung cancer status
CN118522390A (zh) 帮助区别良性和恶性放射线照相明显肺结节的方法和组合物
JP2020522690A (ja) 肺疾病の特定又はモニタリング方法及びシステム
CN108323184A (zh) 验证生物标志物测量
EP2751292A1 (en) Methods and compositions for detecting cancer based on mirna expression profiles
WO2013049152A2 (en) Methods for evaluating lung cancer status
US20250137066A1 (en) Compostions and methods for diagnosing lung cancers using gene expression profiles
WO2021113784A1 (en) Machine learning techniques for gene expression analysis
US20220148677A1 (en) Methods and systems for detecting genetic fusions to identify a lung disorder
US20240327927A1 (en) Active surveillance and risk stratification for prostate cancer
Gómez-Martín et al. Circulating extracellular vesicle isomiR signatures predict therapy response in patients with multiple myeloma
US20250305051A1 (en) Systems and methods of diagnosing idiopathic pulmonary fibrosis
Berndt et al. A multivariate cell-based assay for blood-based diagnostics enhances lung cancer risk stratification
WO2022120076A1 (en) Clinical classifiers and genomic classifiers and uses thereof

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: VERACYTE, INC.

Free format text: FORMER APPLICANT(S): ALLEGRO DIAGNOSTICS CORP.

FGA Letters patent sealed or granted (standard patent)